Literature DB >> 14747420

"Cocktail" approaches and strategies in drug development: valuable tool or flawed science?

Honghui Zhou1, Zeen Tong, James F McLeod.   

Abstract

There is an increasing interest in the simultaneous administration of several probe substrates to characterize the activity of multiple drug-metabolizing enzymes, the so-called "cocktail" approach. However, this method remains controversial and is being investigated more extensively. No general consensus has emerged on the applicability of this approach in clinical investigation and during drug development. The objective of the article is to review this important yet specialized technique, as well as its merits, drawbacks, and potential application in drug development. Among the two-, three-, four-, five-, and six-drug in vivo cocktails previously evaluated in humans, a variety of substrate probe combinations have been studied. Some probe combinations have been validated not to interact in vivo and have been useful in characterizing drug-drug interaction potential and metabolic enzyme induction in humans. For drug candidates that affect two or more in vitro pathways or are potential gene inducers, the use of a cocktail approach may facilitate the rapid delineation of the drug candidate's drug interaction potential. It may also offer the potential of providing clear guidance on safely conducting larger clinical studies and limiting comedication restrictions to only those likely to be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747420     DOI: 10.1177/0091270003261333

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  22 in total

1.  Enhancing the mechanical stability of proteins through a cocktail approach.

Authors:  Yi Cao; Yongnan Devin Li; Hongbin Li
Journal:  Biophys J       Date:  2011-04-06       Impact factor: 4.033

Review 2.  Phase 0/microdosing approaches: time for mainstream application in drug development?

Authors:  Tal Burt; Graeme Young; Wooin Lee; Hiroyuki Kusuhara; Oliver Langer; Malcolm Rowland; Yuichi Sugiyama
Journal:  Nat Rev Drug Discov       Date:  2020-09-08       Impact factor: 84.694

Review 3.  Update on Therapeutic Protein-Drug Interaction: Information in Labeling.

Authors:  Xing Jing; Ping Ji; Sarah J Schrieber; Elimika P Fletcher; Chandrahas Sahajwalla
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

4.  The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers.

Authors:  Andrew K L Goey; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Eur J Clin Pharmacol       Date:  2013-07-24       Impact factor: 2.953

5.  Effects of long-term smoking on the activity and mRNA expression of CYP isozymes in rats.

Authors:  Xiao-Meng He; Ying Zhou; Ming-Zhen Xu; Yang Li; Hu-Qun Li; Wei-Yong Li
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

6.  Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.

Authors:  Sandrine Turpault; William Brian; Robert Van Horn; Alix Santoni; Franck Poitiers; Yves Donazzolo; Xavier Boulenc
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

7.  Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.

Authors:  Ole Kristian Thu; Olav Spigset; Odd Georg Nilsen; Bent Hellum
Journal:  Eur J Clin Pharmacol       Date:  2015-11-28       Impact factor: 2.953

8.  Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport.

Authors:  Kristina K Wolf; Sapana Vora; Lindsey O Webster; Grant T Generaux; Joseph W Polli; Kim L R Brouwer
Journal:  Toxicol In Vitro       Date:  2009-08-23       Impact factor: 3.500

9.  Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.

Authors:  Tobias Klaassen; Alexander Jetter; Dorota Tomalik-Scharte; Dirk Kasel; Julia Kirchheiner; Ulrich Jaehde; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-12-11       Impact factor: 2.953

10.  A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.

Authors:  Peter N Morcos; Linda Chang; Rohit Kulkarni; Mylene Giraudon; Nancy Shulman; Barbara J Brennan; Patrick F Smith; Jonathan Q Tran
Journal:  Eur J Clin Pharmacol       Date:  2013-07-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.